Trifft mich mit voller Wucht die 2. Nebenwirkung
#Inclisiran

Paradoxer LDL-Anstieg unter Inclisiran (LEQVIO) Das arznei-telegramm informiert - unabhängig. kritisch. anzeigenfrei.

Paradoxer #LDL-Anstieg unter #Inclisiran (LEQVIO)

LDL-Anstiege unter Inclisiran sind nach Vortherapie mit PCSK9-Antikörpern sowie auch unabhängig davon beschrieben und können für Monate nachweisbar sein.
www.arznei-telegramm.com/de/6469/para...

Inclisiran offers additional treatment option for adolescents with HeFH The siRNA therapeutic inclisiran significantly reduces LDL cholesterol versus placebo in adolescents undergoing treatment for heterozygous familial hypercholesterolemia, according to the findings of…

#MedNews - The siRNA therapeutic #inclisiran significantly reduces LDL-C vs placebo in adolescents undergoing treatment for heterozygous familial #hypercholesterolemia, according to the findings of the ORION-16 study.

Full story 👉 buff.ly/rEtP04W

#CardioSky

Leqvio (inclisiran) | Relatório de avaliação de financiamento público disponível na Infomed Infarmed

Leqvio (inclisiran) | Relatório de avaliação de financiamento público disponível na Infomed
www.infarmed.pt/web/infarmed...
#infarmed #medicamentos #financiamentopublico #leqvio #inclisiran

We know Inclisiran is a game-changer for lowering LDL. But does it work equally well for Heterozygous (HeFH) and the rare, severe Homozygous (HoFH) form?

doi.org/10.1097/MS9.0000000000002982

#WeiPublications #CardioSky #Lipidology #MedSky #Cardiology #Genetics #Inclisiran #FOAMed

Inclisiran wirksamer und verträglicher als Standard-Therapie ESC 2025 | VICTORION-Difference: Vorteile für Inclisiran vs. Placebo bei Hypercholesterinämie und hohem kardiovaskulärem Risiko. Von Prof. U. Laufs.

✨ #ESCCongress 2025: #Inclisiran (PCSK9-siRNA) senkt LDL-C stärker & ist verträglicher als Standard-Therapie – 📊 Ergebnisse der Phase-4-Studie (VICTORION-Difference) mit 1.776 Patienten vorgestellt von Prof. U. Landmesser & kommentiert von Prof. U. Laufs.
➡️ herzmedizin.de/fuer-...
#CardioSky

Inclisiran monotherapy significantly reduces LDL-C in patients at low ASCVD risk Treatment with inclisiran, a PCSK9 protein blocker, significantly reduces low-density lipoprotein cholesterol in adults at low risk for atherosclerotic cardiovascular disease.

#MedNews - Treatment with #inclisiran, a PCSK9 protein blocker, significantly reduces low-density lipoprotein cholesterol in adults at low risk for #ASCVD.

Full story 👉 buff.ly/p4S9fcn

#CardioTwitter

Inclisiran prescribed to 7% of expected target population in three years, NHS data reveal Fewer than 20,000 people in England have been prescribed anticholesterol drug inclisiran (Leqvio; Novartis) in primary care since 2021, despite expectations set by the NHS that 300,000 people would…

Exclusive: Fewer than 20,000 people in England have been prescribed anticholesterol drug #inclisiran in primary care since 2021, despite expectations set by the NHS that 300,000 people would be taking the drug by 2024

#leqvio #novartis

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial - PubMed Inclisiran was generally well-tolerated in primary prevention patients with elevated LDL-C, who derived significant reductions in atherogenic lipoprotein levels with twice-yearly maintenance dosing.

pubmed.ncbi.nlm.nih.gov/36331315/

The #ORION study for #inclisiran reduces LDL, no clinical outcomes in this specific reference.

📌 #Inclisiran administration potently & durably lowers LDL-C over an extended-term follow-up: the #ORION8 trial
https://buff.ly/4fNrpQh